Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuela Pesce

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Pediatric Pulmonology|August 30, 2024
Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutationsValentina Fainardi, Federico Cresta, Claudio Sorio, et al.
Future Medicinal Chemistry|December 16, 2014
The search for a common structural moiety among selected pharmacological correctors of the mutant CFTR chloride channelErika Nieddu, Benedetta Pollarolo, Marco T Mazzei, et al.
European Journal of Medicinal Chemistry|January 20, 2021
In silico drug repositioning on F508del-CFTR: A proof-of-concept study on the AIFA libraryAlessandro Orro, Matteo Uggeri, Marco Rusnati, et al.
Pharmaceuticals (Basel, Switzerland)|March 26, 2022
Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological AssaysAlice Parodi, Giada Righetti, Emanuela Pesce, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 4, 2026
Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessmentValeria Capurro, Emanuela Pesce, Federico Cresta, et al.
International Journal of Molecular Sciences|April 13, 2023
Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR ModulatorsVito Terlizzi, Emanuela Pesce, Valeria Capurro, et al.
The Journal of Biological Chemistry|November 22, 2017
High-throughput screening identifies FAU protein as a regulator of mutant cystic fibrosis transmembrane conductance regulator channelValeria Tomati, Emanuela Pesce, Emanuela Caci, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 15, 2016
Evaluation of a systems biology approach to identify pharmacological correctors of the mutant CFTR chloride channelEmanuela Pesce, Giulia Gorrieri, Francesco Sirci, et al.
European Journal of Medicinal Chemistry|September 24, 2020
Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assaysAlice Parodi, Giada Righetti, Emanuela Pesce, et al.
Chemmedchem|May 31, 2022
Towards Innovative Antibacterial Correctors for Cystic Fibrosis Targeting the Lung Microbiome with a Multifunctional EffectMaria Grazia Martina, Filomena Sannio, Emmanuele Crespan, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Pediatric Pulmonology|August 30, 2024
Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutationsValentina Fainardi, Federico Cresta, Claudio Sorio, et al.
Future Medicinal Chemistry|December 16, 2014
The search for a common structural moiety among selected pharmacological correctors of the mutant CFTR chloride channelErika Nieddu, Benedetta Pollarolo, Marco T Mazzei, et al.
European Journal of Medicinal Chemistry|January 20, 2021
In silico drug repositioning on F508del-CFTR: A proof-of-concept study on the AIFA libraryAlessandro Orro, Matteo Uggeri, Marco Rusnati, et al.
Pharmaceuticals (Basel, Switzerland)|March 26, 2022
Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological AssaysAlice Parodi, Giada Righetti, Emanuela Pesce, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 4, 2026
Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessmentValeria Capurro, Emanuela Pesce, Federico Cresta, et al.
International Journal of Molecular Sciences|April 13, 2023
Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR ModulatorsVito Terlizzi, Emanuela Pesce, Valeria Capurro, et al.
The Journal of Biological Chemistry|November 22, 2017
High-throughput screening identifies FAU protein as a regulator of mutant cystic fibrosis transmembrane conductance regulator channelValeria Tomati, Emanuela Pesce, Emanuela Caci, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 15, 2016
Evaluation of a systems biology approach to identify pharmacological correctors of the mutant CFTR chloride channelEmanuela Pesce, Giulia Gorrieri, Francesco Sirci, et al.
European Journal of Medicinal Chemistry|September 24, 2020
Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assaysAlice Parodi, Giada Righetti, Emanuela Pesce, et al.
Chemmedchem|May 31, 2022
Towards Innovative Antibacterial Correctors for Cystic Fibrosis Targeting the Lung Microbiome with a Multifunctional EffectMaria Grazia Martina, Filomena Sannio, Emmanuele Crespan, et al.
Pageof 5